2 b
bo An 8th oo
d
A oK sA Feb K b
n
d bY v Ru Y
sA 31 e AR
ve st m £3 Y
0
£1 ARc 0
00 h

Big Data in Pharma
SMi present t...
big data in pharma

www.pharmab

day one i monday 12th may 2014
8.30

Registration & coffee

9.00

chairman's opening Rema...
big data in pharma

bigdata.co.uk
8.30
9.00

day two i tuesday 13th may 2014

Registration & coffee

2.30

chairman's open...
hAlF-dAY post-conFeRence WoRKshop A
Wednesday 14th may 2014 i 8.30am – 12.30pm
holiday inn Regents park hotel, london, uK
...
hAlF-dAY post-conFeRence WoRKshop b
Wednesday 14th may 2014 i 1.30pm – 5.30pm
holiday inn Regents park hotel, london, uK

...
biG dAtA in phARmA

£1198.00

+ vAt £718.80
+ VAT

conference: monday 12th – tuesday 13th may 2014, holiday inn Regents pa...
Upcoming SlideShare
Loading in …5
×

SMi Group's Inaugural Big Data in Pharma conference

757 views

Published on

SMi Group's Inaugural Big Data in Pharma conference takes place in London this May

Published in: Education, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
757
On SlideShare
0
From Embeds
0
Number of Embeds
13
Actions
Shares
0
Downloads
5
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

SMi Group's Inaugural Big Data in Pharma conference

  1. 1. 2 b bo An 8th oo d A oK sA Feb K b n d bY v Ru Y sA 31 e AR ve st m £3 Y 0 £1 ARc 0 00 h Big Data in Pharma SMi present their inaugural conference on… Manage and analyse big data to enhance R&D and clinical trials for the future! 12th - 13th Holiday Inn Regents Park Hotel, London, UK MAY 2014 chairman simon holt, Vice President, Global Head HEOR, novartis pharma AG Prior to this position Simon was the Global Head of Market Access for the franchise responsible for specialty medicines at Novartis. He is based in Basel. Simon brings a background in strategy and operations management consulting from A.T.Kearney with him to his role as well as a wide reaching international network of seniors in the medical device, healthcare, pharmaceutical and diagnostic industries. Key speakers include: • nick brown, Innovation & Technology Architect, Chief Technology Office, AstraZeneca • stephanie manson, Director Global Health Outcomes, GlaxosmithKline • Rob thwaites, Vice President, Health Economics and Epidemiology, evidera and Chair, Pharmaceutical industry Health Information Group, Abpi • Xavier olba, Digital Business Strategy, sanofi Aventis • Jan hauß, Head of R&D Laboratory Information Management System (LIMS), merck KGaA • dr Athula herath, Statistical Director, R&D Statistics, medimmune • Rachel uphill, Enterprise / Information Architect, R&D IT Solutions, Delivery & Integration, GsK medicines Research centre • Kerstin Kleese van dam, Associate Division Director, Leader Scientific Data Management Group, pacific northwest national laboratory benefits of attending: • Attend the only event to focus specifically on the impact of big data in the pharmaceutical industry - how can you exploit its potential to create better medicine and generate new revenue streams? • Hear from knowledgeable speakers - our carefully researched programme includes several exclusive case-studies from pharma and biotechnology experts. Watch this space as more are announced! • Discover how big data analysis can positively impact clinical trials by acting on information in real-time • Gain up to date insight on applications for heoR data in pharma plus tWo inteRActive hAlF-dAY post-conFeRence WoRKshop Wednesday 14th may 2014, holiday inn Regents park hotel, london, uK A: legal and practical Aspects of cloud computing Workshop Leader: Jan hauß, head of R&d laboratory information management system (lims), merck KGaA 8.30am - 12.30pm b: designing and commissioning studies using big data to support drug development and marketing Workshop Leadesr: Rob thwaites, Vice President, Health Economics and Epidemiology, evidera and Chair, Pharmaceutical industry Health Information Group, Abpi Andrew paul cox, phd, Senior Research Associate, evidera Radoslaw (Radek) Wasiak, phd, mA, msc, EU Director and Senior Research Scientist in Health Economics, evidera www.pharmabigdata.co.uk 1.30pm – 5.30pm 1.30 pm - 5.30 pm Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 AcAdemic & GRoups discounts AvAilAble #bigdatapharma2014
  2. 2. big data in pharma www.pharmab day one i monday 12th may 2014 8.30 Registration & coffee 9.00 chairman's opening Remarks simon holt, Vice President, Global Head HEOR, novartis pharma AG biG dAtA in clinicAl tRiAls 11.40 personalized medicine: using big data to individualize treatment; the cancer example • Reviewing constitutional factors influencing reaction of the host on a drug • Discussing cancer/host factors predicting clinical course, i.e. prognosis • Tumour cell biology identifying validated tumor-driving genomic aberrations in drug-targeted genes/pathways ('predictive' biomarkers) professor hubert caron, Paediatric Oncology, emma children’s hospital Amc Academic medical centre, university of Amsterdam 12.20 networking lunch 1.50 leveraging existing data from legacy clinical trials • Discover a goldmine at your fingertips • Understanding how to prepare it for use • Choice of a (set of) standard(s) • Evaluating future developments pantaleo nacci, Head Statistical Safety and Epidemiology/PV, novartis vaccines and diagnostics 2.30 developing a robust and effective patient reported outcomes (pRo) strategy for clinical trials • Understanding the essential elements required to create a successful PRO strategy • Ensuring best practice for PRO use in trials, to improve the quality of PRO information collected for: - clinical care - decision-making - predicting long-term outcomes - informing health policy professor melanie calvert, Professor of Outcomes Methodology, Primary Care Clinical Sciences, birmingham university 3.10 Afternoon tea mAnAGement And AnAlYsis (pARt 1) 9.10 9.50 openinG AddRess big data analytics…enabling the "insights from the whole patient populations to a sample • On development of a framework that may enable the analysis of clinical data/standard care in real-time to keep abreast of latest clinical research related to drug development • Introducing high-performance analytics to enable timely and accurate insights using - data mining - predictive analytics - modelling and simulation of the possible outcomes of a therapeutic intervention to stratify patient populations to sieve through the best interventions for a patient strata dr Athula herath, Statistical Director, R&D Statistics, medimmune big data and the pharmaceutical industry: understanding how industry initiatives can move opportunities with big data forward for individual companies • How has industry championed big data?...Examples from multiple countries • Case study - a decade of initiatives by industry in the UK • Collaborative developments that will open up opportunities for companies in the future • How can developments at an industry level help a company’s RWD strategy Rob thwaites, Vice President, Health Economics and Epidemiology, Evidera and Chair, Pharmaceutical industry Health Information Group, Abpi looKinG AheAd 10.30 morning coffee 3.40 beyond the horizon… building the ‘blueprint’ for a data-led pharmaceutical industry of the future • Understanding how the plethora of new data and improved analytical techniques can enhance future innovation and feed the drug-development pipeline • Implementing standards, strategies and collaborations to enhance products and provide wider medical value • Discovering what your peers are prioritizing as part of their own Big Dip strategies Rachel uphill, Enterprise / Information Architect, R&D IT Solutions, Delivery & Integration, GsK medicines Research centre 11.00 leveraging big data to study comparative effectiveness research (ceR): a case example in multiple sclerosis • Developing a systematic approach for identifying CER opportunities for pharma • MS is a complex, chronic disease that requires monitoring of real-world effectiveness to inform clinical and economic decision-making • The use of data from multiple sources can overcome the limitations associated with assessing outcomes using a single source of information, such as individual database or registry studies • This combination of data sources provides useful critical information on real-world outcomes in a general MS population that can be used to complement data from clinical trials and observational studies in MS niklas bergvall, Senior Director, Global HE&OR Neuroscience, novartis pharma 4.20 An lessons learned so far! understanding big data and disc el ussio its uses for the pharmaceutical world n • What has been learned • Evaluating what has and hasn’t worked • What are the next steps in the big data strategy dr Athula herath, Statistical Director, R&d statistics, medimmune pantaleo nacci, Head Statistical Safety and Epidemiology/PV, novartis vaccines and diagnostics 5.00 chairman's closing Remarks and close of day one p sponsoRship And eXhibition oppoRtunities smi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia malick, director on+44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk *Subject to final confirmation Want to know how you can get involved? interested in promoting your services to this market? contact humaira Kaiser, smi marketing on +44 20 7827 6197, or email: hkaiser@smi-online.co.uk Register online at: www.pharmabigdata.co.uk • Alternatively fax y
  3. 3. big data in pharma bigdata.co.uk 8.30 9.00 day two i tuesday 13th may 2014 Registration & coffee 2.30 chairman's opening Remarks dr Athula herath, Statistical Director, R&D Statistics, medimmune love thy neighbour - creating stakeholder partnerships to maximize expertise capabilities and develop innovative medicines • Understanding how collaboration can enhance drug research, development, commercialization and delivery • Evaluating how collaborative “open space” initiatives can enable specific questions or share insights to be addressed • Learn how partnerships can harnessing Big Data for the development of innovative medicines • Lessons learned from successful pharmaceutical, academic and CRO collaborations • Building strategic relationships to maximize quality improvements, economic value and cost effective outcomes nick brown, Innovation & Technology Architect, Chief Technology Office, AstraZeneca pAn Kerstin Kleese van dam, Associate Division Director, disc el ussio n Leader Scientific Data Management Group, pacific northwest national laboratory stephanie manson, Director Global Health Outcomes, GlaxosmithKline 3.10 Afternoon tea mAnAGement And AnAlYsis (pARt 2) 9.10 9.50 10.30 11.00 11.40 12.20 1.50 openinG AddRess observational research and heoR in the big data arena • Understanding the various applications for HEOR data in pharmaceuticals – an introduction to the value of HEOR • Reviewing examples of how HEOR data has proved important and how this might be impacted by the use of big data • Big data sources of real world observational data • Embedding real-world data collection into clinical development programmes stephanie manson, Director Global Health Outcomes, GlaxosmithKline discussing advances in predictive analytics • In-depth analysis – how to get at the hidden nuggets in your data • New approaches to distributed data analysis – analytics @ the edge • Continuous, automated synthesis of new knowledge and dynamic control - analysis in motion Kerstin Kleese van dam, Associate Division Director, Leader Scientific Data Management Group, pacific northwest national laboratory morning coffee mARKetinG & sociAl mediA 3.40 improving pharmaceutical marketing performance using big data solutions • Developing a digital marketing strategy in the data age • Leveraging social media to communicate your key brand messaging and intent • Managing and optimising clinical data to stay ahead of the complex and challenging market environment • Generate more informative evidence across the product lifecycle with observational data christopher Keenan, Director, Governance & Operations, Global Medical Information, bms* 4.20 delivering a definitive social media strategy and culture within pharma to deliver optimal patient healthcare and treatment awareness • Realizing how social media can be used to meet the goals for better understanding patients and to find out about: - unmet need - new adverse events - patient compliance • Evaluating available opportunities within social media for drug marketing • Understanding how to effectively market your drugs via social media • Deciphering how the various popular mediums can be used – twitter, YouTube, LinkedIn and Facebook • Preparing for the challenges of drug advertising compliance within social media Xavier olba, Digital Business Strategy, sanofi 5.00 chairman’s closing Remarks and close of day two the impAct oF biG dAtA on ReseARch And development making the right connections! integrating data to guarantee consistency and reliability in R&d • Managing and integrating data generated at all stages of the value chain, from discovery to real-world use, to derive maximum benefit from technology trends • Implementing strategies to integrate external and internal content Jan hauß, Head of R&D, laboratory information management system (LIMS), merck KGaA unlocking the power of big data to transform R&d productivity • Measuring the value of big data to pharmaceutical R&D • How to Ensure you Select the Right ELN for your R&D • Identifying the right patients for the right drug in Phase II trial stage using Big Data usman iqbal, Senior Director of Oncology, Global Evidence & Value Development, R&d/ med Affairs, sanofi networking lunch cReAtinG A biG dAtA oRGAnisAtionAl cultuRe & buildinG stRAteGic pARtneRships big data, small steps…. insight into our innovation network and how nurturing small pilots that deliver value, lead to big business change • Realizing the importance of nurturing innovation • Utilizing pilots and proof-of-concept • Evaluating crowd-sourcing big data nick brown, Innovation & Technology Architect, Chief Technology Office, AstraZeneca supported by your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 *Subject to final confirmation
  4. 4. hAlF-dAY post-conFeRence WoRKshop A Wednesday 14th may 2014 i 8.30am – 12.30pm holiday inn Regents park hotel, london, uK legal and practical Aspects of cloud computing Workshop Leader: Jan hauß, Head of R&D Laboratory Information Management System (LIMS), merck KGaA overview of workshop: After the latest scandals (e.g. PRISM) there should be a focus on legal and economical traps and pitfalls in cloud computing. Legal aspects are: • ISO 27K regulations • Local and EU directives concerning privacy Economical aspects are • Data leakage prevention • IP protection This workshop will allow you to get a better understanding of what to be aware of. Why you should attend: Gain practical and timely advice for anybody who is involved in planning and implementation of software and services that are Cloud based. In practice that means that sharing data with an CRO via third party services is sometimes for legal reasons not acceptable. If you are involved in this area this workshop is for you. programme: 8.30 Registration and coffee 9.00 9.10 9.50 10.30 11.00 11.40 12.20 12.30 opening remarks session 1 iso 27K regulations session 2 business relevant local and eu directives concerning privacy coffee break session 3 data leakage prevention session 4 ip protection closing remarks end of workshop  About the workshop host: Jan was born in 1962. He achieved a Ph.D. in Heidelberg in chemistry 1993, a Post Doc. in Sussex in 1995 and has been an IBM Fellow from 1996-1998. Since 1998 Jan has worked with Merck KGaA. He joined the company initially as Lab. head NMR. He has since moved onto different positions responsible for the R&D LIMS and local IT Security Officer for Site Operations. About the merck Group In 2012, the Merck Group generated total revenues of €11.2 billion. The Merck Serono division accounted for €6.4 billion, the Consumer Health division for €475 million, the Performance Materials division for €1.7 billion and the Merck Millipore division for € 2.6 billion of that total. EBITDA pre, with which the earning power of operating activities is measured, climbed to €3 billion. Research and development spending amounted to €1.5b illion. The operating result totaled €964 million and free cash flow was €2 billion. Important and current information on the company can be found on the Web at www.merckgroup.com
  5. 5. hAlF-dAY post-conFeRence WoRKshop b Wednesday 14th may 2014 i 1.30pm – 5.30pm holiday inn Regents park hotel, london, uK designing and commissioning studies using big data to support drug development and marketing Workshop Leaders: Rob thwaites, Vice President, Health Economics and Epidemiology, evidera and Chair, Pharmaceutical industry Health Information Group, Abpi Andrew paul cox, PhD, Senior Research Associate, evidera Radoslaw (Radek) Wasiak, phd, mA, msc, EU Director and Senior Research Scientist in Health Economics, evidera overview of workshop: The purpose of the workshop is to give participants the basic tools to evaluate whether and how to commission a big data study. The topics that will have been presented at the conference over the preceding two days will give all attendees a picture of where studies using big data can contribute in big pharma. This half day workshop will concentrate on the “how”: how to decide when a study using big data makes sense; how to commission a piece of work using big data; and how to make the most of the investment in a big data project. Why you should attend: Through a series of frameworks and case studies, the workshop leaders will provide information and insights on: • Reviewing different types of big data studies that can be brought into support a new drug • Planning for evidence generation: when can big data studies best be brought in….and what are the alternatives? • Pitfalls to avoid in the design, conduct and analysis of big data studies • Newer methods and approaches to consider • Selecting partners for a big data study programme: 1.30 Registration and coffee 2.10 session 1 Reviewing the different types of big 2.00 2.50 3.20 3.50 4.30 4.50 5.20 5.30 opening remarks data studies that can be brought into support a new drug session 2 planning for evidence generation: when can big data studies best be brought in…and what are the alternatives? coffee break session 3 pitfalls to avoid in the design, conduct and analysis of big data studies session 4 newer methods and approaches to consider session 5 selecting partners for a big data study closing remarks end of workshop About the workshop hosts: Rob thwaites, mA, mcom, is Vice President, Health Economics and Epidemiology, for Evidera, a leading global scientific consulting organisation. Rob is been responsible for teams in Europe conducting projects in the areas of health economics, outcomes research, and market access. As Chair of the UK Pharmaceutical industry Health Information Group, Rob leads the team at the Association of the British Pharmaceutical Industry responsible for activities at an industry level to encourage the development and use of big data and associated capabilities. Andrew paul cox, phd, is a Senior Research Associate at Evidera. In his role at Evidera, his main area of expertise is Epidemiology, mathematical modelling and data science. Radoslaw (Radek) Wasiak, phd, mA, msc, is an EU Director and Senior Research Scientist in Health Economics at Evidera in London, UK. He has extensive applied research experience in designing and executing health economic, health services, and multidisciplinary research.
  6. 6. biG dAtA in phARmA £1198.00 + vAt £718.80 + VAT conference: monday 12th – tuesday 13th may 2014, holiday inn Regents park hotel, london, uK i Workshops: Wednesday 14th may 2014, london 4 WAYs to ReGisteR online www.pharmabigdata.co.uk FAX your booking form to +44 (0) 870 9090 712 phone on +44 (0) 870 9090 711 our Reference VENUE deleGAte detAils Forename: surname: Job title: company/organisation: total £2697.00 + vAt £3236.40 £2098.00 + vAt £2517.60 £1499.00 + vAt £1798.80 £599.00 The Conference fee includes refreshments, lunch, conference papers and CD ROM containing all of the presentations. email: company vAt number: Address: live stReAminG/on demAnd/documentAtion town/city: post/Zip code: country: direct tel: direct Fax: mobile: switchboard: signature: I agree to be bound by SMi's Terms and Conditions of Booking. Accounts dept title: surname: date: Forename: Address (if different from above): post/Zip code: unable to travel, but would like to watch the conference ask questions, participate as if you were in the room? price □ Live Streaming £999.00 □ On demand £599.00 (available 24 hours after the event) □ Access to the conference documentation on the Document Portal £499.00 □ The Conference Presentations – paper copy £499.00 (or only £300 if ordered with the Document Portal) live, + vAt £598.80 £499.00 pAYment email: direct tel: □ Conference & 2 Workshops □ Conference & 1 Workshop □ Conference only □ 1 Workshop only □ 2 Workshops only Workshop A □ Workshop B □ total + vAt £1198.80 + vAt £718.80 GRoup discounts AvAilAble pRomotionAl liteRAtuRe distRibution □ Distribution of your company’s promotional literature to all conference attendees £999.00 department/division: town/city: book by 31st march to receive £100 off the conference price i would like to attend: (please tick as appropriate) Fee Please complete fully and clearly in capital letters. Please photocopy for additional delegates. title: book by 28th February to receive £300 off the conference price conFeRence pRices p-103 + vAt £1198.80 south, harling house, 47-51 Great suffolk street, london, se1 0bs, uK eARlY biRd □ discount □ unique Reference number £1437.60 post your booking form to: events team, smi Group ltd, 2nd Floor country: direct Fax: holiday inn Regents park, carburton st, london W1W 5ee □ please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 terms and conditions of booking payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. substitutions/name changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. data protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. Payment must be made to smi Group ltd, and received before the event, by one of the following methods quoting reference p-103 and the delegate’s name. bookings made within 7 days of the event require payment on booking, methods of payment are below. please indicate method of payment: □ uK bAcs □ Wire transfer □ cheque □ credit card Sort Code 300009, Account 00936418 Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): loYdGb21013, Account 00936418 IBAN Gb48 loYd 3000 0900 9364 18 We can only accept Sterling cheques drawn on a UK bank. □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card cardholder’s name: signature: I agree to be bound by SMi's Terms and Conditions of Booking. date: card billing Address (If different from above): vAt VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here if you have any further queries please call the events team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk

×